Research & Development

Dr. Reddy’s Laboratories announces acquisition of ANDA portfolio

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced today that it has entered into a definitive agreement to acquire a portfolio of 42 approved, non-marketed Abbreviated New Drug Applications (ANDAs) in the U.S.

AAV gene therapy company AskBio secures $235m investment

Asklepios BioPharmaceutical (AskBio) has secured an investment of $235m to accelerate its business of developing and manufacturing Adeno-Associated Virus (AAV) gene therapies for rare and generally untreatable genetic disorders.

Alnylam, Regeneron collaboration to discover, develop and commercialize RNAi therapeutics

Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced a collaboration to discover, develop and commercialize new RNA interference (RNAi) therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system (CNS), in addition to a select number of targets expressed in the liver.

Celltrion, iProgen Biotech join forces to develop antibody-drug conjugates

Celltrion has entered into a partnership with iProgen Biotech, a pre-clinical stage Canadian biotechnology company, for the development of a series of antibody-drug conjugates against HER21 and CD20 and other validated antibody targets.

Alnylam, Sanofi conclude research and option phase of 2014 RNAi therapeutics collaboration

Alnylam Pharmaceuticals and Sanofi have agreed to conclude the research and option phase of the companies’ 2014 RNAi therapeutics alliance in rare genetic diseases.

Twist Bioscience and LakePharma form strategic collaboration to provide antibody discovery and development services

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and LakePharma, Inc., the leading US-based biologics CRDMO, today announced a strategic collaboration to offer antibody discovery and development solutions to pharmaceutical and biotechnology customers.

Xencor, Astellas Pharma collaborate on novel bispecific antibody program

Clinical-stage biopharmaceutical firm Xencor has entered into a research collaboration with Astellas Pharma for novel bispecific antibody program.

Novartis to acquire anti-inflammatory drugmaker IFM Tre in $1.6bn deal

Swiss pharma giant Novartis has agreed to acquire IFM Tre from US biopharma company IFM Therapeutics in a deal worth up to $1.575bn, to add certain immunomodulatory medicines to its portfolio.

Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe

Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and commercialize NERLYNX (neratinib) within Europe and part of Africa.